FDA approved a new medicine Sprix

FDA approved a new medicine Sprix

The US Food and Medicines Administration approved the medication Sprix (ketorolac trometamin) in the form of nasal spray for short-term treatment of moderate and severe pain.

Nasal spray Sprix contains nonsteroidal anti-inflammatory remedy (NSAID) ketorolac. This non-narcotic medication minimizes the risk of abuse and non-medicinal use and also reduces the risk of serious side effects.

The medicine should not be used for more than 5 days. Also, Sprix is contraindicated in patients with peptic ulcer disease and renal insufficiency.

The manufacturer of the remedy is the company Roxro Pharma.



Feb 23, 2014